John Libbey Eurotext

European Journal of Dermatology

Treatment patterns and outcomes for patients with locally advanced basal cell carcinoma before availability of Hedgehog pathway inhibitors: a retrospective chart review Article à paraître

Illustrations

  • Figure 1
  • Figure 2
  • Figure 3
  • Figure 4

Tableaux

Auteurs
1 Manchester Academic Health Science Centre,
Manchester University,
and Manchester Royal Infirmary,
Manchester,
United Kingdom
2 Hôpital Saint-Louis,
Paris,
France
3 Klinik für Hautkrankheiten und Allergologie SRH Wald-Klinikum Gera GmbH,
Gera,
Germany; Klinik für Hautkrankheiten,
Universitätsklinikum,
Jena,
Germany
4 Hôpital Saint-Andre,
CHU de Bordeaux,
Dermatology,
Bordeaux,
France
5 University of Lille,
INSERM U1189,
CHRU Lille,
France
6 IRCCS,
Referral Cancer Center of Basilicata,
Rionero in Vulture,
Italy
7 Western Infirmary,
Glasgow,
United Kingdom
8 Medical Faculty Mannheim,
Heidelberg University,
Mannheim,
Germany
9 F. Hoffmann-La Roche Ltd.,
Basel,
Switzerland
10 Hôpital de la Timone,
Marseille,
France
* Reprints
a Deceased (16 February 2016)

Background

Understanding the molecular basis of basal cell carcinoma (BCC) has led to development of Hedgehog pathway inhibitors (HPIs) for patients with advanced forms of BCC (aBCC). A practical definition of aBCC as a distinct disease entity is unavailable, and epidemiological information is limited.